PPT
FDA’s Regulation of Products Derived Through Nanotechnology: Controversies and Potential Impacts on Nanomedicine Ricardo Carvajal Hyman, Phelps & McNamara,
Meeting the Challenges of Blood, Vaccine, and Tissue Safety Jesse L. Goodman, MD, MPH Director, Center for Biologics Evaluation and Research (CBER) Presentation.
FDA Science Board, April 2003
Click to edit Master subtitle style. CDRH Vision - Total Product Life Cycle.
CDRH Vision - Total Product Life Cycle
